Those are some solid endorsements.
News & Analysis: Invitae
Investors appear to like the company's new collaboration with PacBio.
NVTA earnings call for the period ending September 30, 2020.
The medical genetics company easily topped Wall Street's top- and bottom-line estimates in the third quarter.
Which stock wins in this genetics version of David versus Goliath?
Not all of the genetic tests it sells were particularly in demand as the COVID-19 pandemic intensified.
NVTA earnings call for the period ending June 30, 2020.
After a $1.4 billion merger, can Invitae become an industry leader in genetic testing and cancer diagnostics?
Illumina is practically an institution in the biotech sector, but can it outgrow an aggressive competitor?
The combination of the two companies will create a genetics powerhouse.